Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 8987 results

  1. Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

    Awaiting development Reference number: GID-TA11530 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development Reference number: GID-TA10605 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]

    Awaiting development Reference number: GID-TA11874 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    Awaiting development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Technology for cancer case finding using primary care records

    Awaiting development Reference number: GID-HTG10176 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  7. Wireless breast lesion localization using Savi Scout seed

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]

    Awaiting development Reference number: GID-TA11948 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Luspatercept for treating anaemia caused by myelofibrosis [ID6697]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]

    Awaiting development Reference number: GID-TA11904 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Sentinel Node Biopsy approved for pathological staging of clinically T1-T2 N0 oral cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. High linear energy transfer radiation for carbon ion beam therapy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Technologies to improve the detection of endometrial cancer

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  15. Signatera molecular residual disease assay (MT741)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation